Zhao Cheng-Fei, Liu Xiao-Ling, Wu Ning-Bi, Xu Zhi-Feng
School of Pharmacy and Medical Technology, Putian University, Putian 351100, Fujian Province, China.
Key Laboratory of Pharmaceutical Analysis and Laboratory Medicine in University of Fujian Province, Putian University, Putian 351100, Fujian Province, China.
World J Gastroenterol. 2025 May 7;31(17):104794. doi: 10.3748/wjg.v31.i17.104794.
Gastric cancer (GC), the fifth most common malignancy worldwide, poses a substantial challenge in clinical oncology, particularly in its advanced stages. Despite advancements in immunotherapy, patient prognosis remains poor, underscoring the need for reliable prognostic tools to refine treatment strategies. A study by Yao explores the role of the triglyceride-glucose (TyG) index as a prognostic marker for advanced GC patients receiving immunotherapy combined with chemotherapy. The results of the study demonstrate that the TyG index correlates with improved survival outcomes, including better progression-free survival and overall survival. This editorial critically evaluates the significance of these findings, discusses their implications for future research, and highlights innovative directions that could drive further breakthroughs in the application of the TyG index to cancer therapy. This editorial also highlights the potential of TyG in advancing precision oncology and advocates for global validation and mechanistic investigations to further solidify its clinical utility. Future research should focus on validating the TyG index across various malignancies, exploring its potential to influence immunotherapy through metabolic interventions, and developing multi-biomarker models that integrate TyG with immune and genomic profiles.
胃癌（GC）是全球第五大常见恶性肿瘤，在临床肿瘤学中构成了重大挑战，尤其是在晚期。尽管免疫疗法取得了进展，但患者预后仍然很差，这凸显了需要可靠的预后工具来优化治疗策略。姚的一项研究探讨了甘油三酯-葡萄糖（TyG）指数作为接受免疫疗法联合化疗的晚期GC患者预后标志物的作用。该研究结果表明，TyG指数与改善生存结果相关，包括更好的无进展生存期和总生存期。这篇社论批判性地评估了这些发现的意义，讨论了它们对未来研究的影响，并强调了可能推动TyG指数在癌症治疗应用中取得进一步突破的创新方向。这篇社论还强调了TyG在推进精准肿瘤学方面的潜力，并倡导进行全球验证和机制研究，以进一步巩固其临床效用。未来的研究应侧重于在各种恶性肿瘤中验证TyG指数，探索其通过代谢干预影响免疫疗法的潜力，以及开发将TyG与免疫和基因组特征相结合的多生物标志物模型。
